News & Events
Ghent, Belgium / Rotterdam, The Netherlands / Miami, FL, USA – November 24, 2020 Allero Therapeutics BV, a Belgian-Dutch oromucosal immunotherapy company, and Abbreos Inc., a US- based IND-stage company focused on developing treatments that dampen hyperactive...
Official launch of Immagene: Dutch company developing next-generation immuno-oncology therapeutics Immagene B.V. launched this month as a private biotech company developing next-generation precision immuno-oncology (IO) treatments. The company based in...
3 October 2019 Life sciences seed capital fund Curie Capital today announced the closing of a seed investment in Allero Therapeutics, a biopharmaceutical company focused on the development of novel immunotherapies. The company has developed a proprietary platform...
ROTTERDAM, 17 April 2019 – Swanbridge Capital, an early-stage Life Sciences venture capital fund, today announced the closing of a Seed investment in Allero Therapeutics, a biopharmaceutical company focused on the discovery and development of novel immunotherapies....
DegenRx secures funding for Alzheimer’s disease gene therapy
Swanbridge Capital announced it invested in IPaDiC, a private company developing an implantable insulin pump for diabetes type 1 patients with an insulin resistance.
Abegaill B.V. announces the successfully closing of a seed funding round. This funding is provided by Swanbridge Capital, a Dutch life science venture capital fund, and Leander Healthcare, a Benelux medtech innovation provider.
Swanbridge Capital, a Dutch Life Science Venture Capital fund, today announced its investment in FABPulous B.V., a Dutch start-up company focused on the development of a new diagnostic tool that quickly distinguishes whether patients with chest pains are at urgent risk of a heart attack. Swanbridge Capital co-led the investment round together with Health Innovations.
Swanbridge Capital today announced the launch and closing of its first life science fund. The fund, with a size of €6.5 million, will invest in early stage life sciences ventures that require capital to fund their first Proof of Concept experiments.
Brainpark II - Building XI
3062 ME Rotterdam